Description:
Technoview®Arixtra®ControlLowisaplasmacontrolwithalowconcentrationofArixtra®*(~0.4µg/ml)foruseasaqualitycontrolsampleinresearchmeasurementsoffondaparinuxsodium.Itisoptimizedforusewithanti-Xachromogenicassaysand isfrequentlyusedinconjunctionwiththe Technoview®Arixtra® highcontrolandtheTechnoview®Arixtra® calibratorsetinthe Technochrom®anti-Xachromogenicassay.
*Fondaparinuxsodium istheactivesubstanceinArixtra®.
Advantages:
- 6vialsperkit-providescontrolsetwithalongshelflife
- AllowsforthevalidationofcalibrationcurvesforthemeasurementofArixtra® inplasma
- Optimizedforusewithanti-Xa(withoutexogeneousantithrombin) research assays
ControlSetComposition:
- 6x1mlvials
Controlmaterialislyophilizedandpreparedfrompooledhumancitratedplasmasupplementedwithalow concentrationofArixtra®.TheplasmacontainsstABIlizersbutnobactericideadditives.ItiscalibratedagainsttheInternationalStandardpreparation01/608.
Background:
Arixtra®(fondaparinuxsodium)InjectionisafactorXa(FXa)inhibitordrug.As asyntheticpentasaccharide,itischemicallysimilartolowmolecularweightheparin(LMWH),thoughitisselectiveforFXa.Morespecifically,itshighaffinityantithrombin(AT)binding allowsfor indirectinhibitionofFXa. Useofthisdrugsubstantiallylowerstheriskfor heparin-inducedthrombocytopenia(HIT)andithasnotbeenshownto reactwithHITantibodies.Itisprescribedbyahealthcareproviderandcanbeusedfor:
- prophylaxis ofvenousthromboembolism(VTE)aftermajororthopedicoraBDominalsurgery;or
- treatmentofacuteVTEwhenadmiNISTeredinconjunctionwithwarfarini.e.usedshort-termuntilthewarfarinbloodtestisinthetargetrange.
Inmostcases,Arixtra®doesnotrequireroutinemonitoring.However,itcanbemeasuredusingananti-Xaassaywithappropriatecalibrators(fondaparinuxsodium).Theactivityoffondaparinuxsodiumisexpressedinmgandcannotbecomparedtotheactivitiesofheparinor LMWH.NotethatthiscontrolisforresearchuseonlyintheUSandCanada.
